BioSpace News Archive

Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB, announced that Health Canada has approved DOPTELET®, an oral thrombopoietin receptor agonist, for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment and for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.

Aura Biosciences, Inc. (NASDAQ: AURA) today announced it has received agreement from the U.S. Food and Drug Administration (FDA) under an SPA for the design and planned analysis of CoMpass, the Company’s global Phase 3 clinical trial of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma (CM).

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2023 financial and operating results.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 11 newly-hired employees stock options to purchase an aggregate of 80,700 shares, and restricted stock units covering an aggregate of 38,600 shares, of BioCryst common stock.

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”) today announced results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provided a corporate update.

Theriva Biologics (NYSE American: TOVX) today announced that it plans to host a conference call on Monday, November 13, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2023 and provide a corporate update.

MaxCyte, Inc. announced Company management will participate at two upcoming investor conferences.

BioAtla, Inc. announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held in London, UK November 14–16, 2023.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended September 30, 2023, and provided an update on corporate progress.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report third quarter financial results on Monday, Nov. 13, 2023.